Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
Katherine Sullivan-Reed, Elisabeth Bolton-Gillespie, Yashodhara Dasgupta, et al.
Cell Reports (2018) Vol. 23, Iss. 11, pp. 3127-3136
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Anika Trenner, Alessandro A. Sartori
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 167
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 17
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
Parasvi S. Patel, Arash Algouneh, Razqallah Hakem
Oncogene (2021) Vol. 40, Iss. 17, pp. 3001-3014
Closed Access | Times Cited: 65
Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer
Yang Yi-ren, Yi Mou, Lin‐Xi Wan, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2600-2623
Closed Access | Times Cited: 11
The tumor therapy landscape of synthetic lethality
Biyu Zhang, Chen Tang, Yanli Yao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 54
RAD52: Paradigm of Synthetic Lethality and New Developments
Matthew J. Rossi, Sarah DiDomenico, Mikir Patel, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 43
BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers
Anna P. Loboda, Leonid Adonin, Svetlana Zvereva, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4982-4982
Open Access | Times Cited: 18
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
Meiyi Ge, Jian Luo, Yi Wu, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 7
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
RAD52 Functions in Homologous Recombination and Its Importance on Genomic Integrity Maintenance and Cancer Therapy
Augusto Nogueira, Mara Fernandes, Raquel Catarino, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1622-1622
Open Access | Times Cited: 52
Emerging Roles of RAD52 in Genome Maintenance
Manisha Jalan, Kyrie S. Olsen, Simon N. Powell
Cancers (2019) Vol. 11, Iss. 7, pp. 1038-1038
Open Access | Times Cited: 50
Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
Samuele Lodovichi, Tiziana Cervelli, Achille Pellicioli, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6684-6684
Open Access | Times Cited: 43
Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma
Naoka Tamura, Nadeem Shaikh, Daniel Muliaditan, et al.
Cancer Research (2020) Vol. 80, Iss. 22, pp. 4946-4959
Open Access | Times Cited: 42
The Multiple Facets of ATRX Protein
Martina Valenzuela, Roberta Amato, Antonella Sgura, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2211-2211
Open Access | Times Cited: 39
Nickel nanoparticle-induced cell transformation: involvement of DNA damage and DNA repair defect through HIF-1α/miR-210/Rad52 pathway
Yiqun Mo, Yue Zhang, Yuanbao Zhang, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 39
PARP Inhibitors in Pancreatic Cancer
Timothy J. Brown, Kim A. Reiss
The Cancer Journal (2021) Vol. 27, Iss. 6, pp. 465-475
Open Access | Times Cited: 34
SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52
Yuchao Diao, Yingwei Li, Zixiang Wang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 24
Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks
Hiroshi Onji, Sota Tate, Tomohisa Sakaue, et al.
Oncogene (2024) Vol. 43, Iss. 32, pp. 2475-2489
Open Access | Times Cited: 5
An integrative structural study of the human full-length RAD52 at 2.2 Å resolution
Beatrice Balboni, Roberto Marotta, Francesco Rinaldi, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 5
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
Monika M. Toma, Katherine Sullivan-Reed, Tomasz Śliwiński, et al.
Cancers (2019) Vol. 11, Iss. 10, pp. 1561-1561
Open Access | Times Cited: 42
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Katherine E. Baillie, Peter C. Stirling
Trends in cancer (2020) Vol. 7, Iss. 5, pp. 430-446
Closed Access | Times Cited: 39
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
Alexandre André Balieiro Anastácio da Costa, Glauco Baiocchi
Seminars in Cancer Biology (2020) Vol. 77, pp. 29-41
Closed Access | Times Cited: 37
D-bait: A siDNA for regulation of DNA-protein kinases against DNA damage and its implications in cancer
Devyani Sengar, Nida Sayed Pathan, Virendra Gajbhiye
International Journal of Pharmaceutics (2025) Vol. 673, pp. 125416-125416
Closed Access
NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer
Liam Baird, Masayuki Yamamoto
Molecular and Cellular Biology (2020) Vol. 41, Iss. 2
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top